These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Pyoderma gangrenosum and concomitant hidradenitis suppurativa--rapid response to canakinumab (anti-IL-1β). Jaeger T; Andres C; Grosber M; Zirbs M; Hein R; Ring J; Traidl-Hoffmann C Eur J Dermatol; 2013; 23(3):408-10. PubMed ID: 23816498 [No Abstract] [Full Text] [Related]
7. Hidradenitis suppurativa and concomitant pyoderma gangrenosum: a case series and literature review. Hsiao JL; Antaya RJ; Berger T; Maurer T; Shinkai K; Leslie KS Arch Dermatol; 2010 Nov; 146(11):1265-70. PubMed ID: 21079064 [TBL] [Abstract][Full Text] [Related]
8. Is there a role for infliximab in the current therapy of hidradenitis suppurativa? A report of three treated cases. Moschella SL Int J Dermatol; 2007 Dec; 46(12):1287-91. PubMed ID: 18173525 [TBL] [Abstract][Full Text] [Related]
9. Concurrent hidradenitis suppurativa, inflammatory acne, dissecting cellulitis of the scalp, and pyoderma gangrenosum in a 16-year-old boy. Koshelev MV; Garrison PA; Wright TS Pediatr Dermatol; 2014; 31(1):e20-1. PubMed ID: 24118007 [TBL] [Abstract][Full Text] [Related]
10. Successful treatment of hidradenitis suppurativa with infliximab in a patient who failed to respond to etanercept. Poulin Y J Cutan Med Surg; 2009; 13(4):221-5. PubMed ID: 19706231 [TBL] [Abstract][Full Text] [Related]
11. Pyoderma gangrenosum associated with cystic acne and hidradenitis suppurativa controlled by adding minocycline and sulfasalazine to the treatment regimen. Shenefelt PD Cutis; 1996 May; 57(5):315-9. PubMed ID: 8726710 [TBL] [Abstract][Full Text] [Related]
12. Tumor necrosis factor alpha inhibitors for the treatment of dermatologic diseases. Trent JT; Kerdel FA Dermatol Nurs; 2005 Apr; 17(2):97-107. PubMed ID: 15916184 [TBL] [Abstract][Full Text] [Related]
13. Infliximab for treatment of pyoderma gangrenosum associated with clinically inactive Crohn's disease. A case report. Kouklakis G; Moschos J; Leontiadis GI; Kadis S; Mpoumponaris A; Molyvas E; Minopoulos GI Rom J Gastroenterol; 2005 Dec; 14(4):401-3. PubMed ID: 16400359 [TBL] [Abstract][Full Text] [Related]
14. Dramatic improvement of pyoderma gangrenosum with infliximab in a patient with PAPA syndrome. Stichweh DS; Punaro M; Pascual V Pediatr Dermatol; 2005; 22(3):262-5. PubMed ID: 15916580 [TBL] [Abstract][Full Text] [Related]
15. Infliximab for the treatment of disseminated pyoderma gangrenosum associated with ulcerative colitis. Case report and literature review. Juillerat P; Christen-Zäch S; Troillet FX; Gallot-Lavallée S; Pannizzon RG; Michetti P Dermatology; 2007; 215(3):245-51. PubMed ID: 17823524 [TBL] [Abstract][Full Text] [Related]
16. Spectrum of diseases associated with pyoderma gangrenosum and correlation with effectiveness of therapy: New insights on the diagnosis and therapy of comorbid hidradenitis suppurativa. Fischer AH; Jourabchi N; Khalifian S; Lazarus GS Wound Repair Regen; 2022 May; 30(3):338-344. PubMed ID: 35385180 [TBL] [Abstract][Full Text] [Related]
17. Treatment of hidradenitis suppurativa with infliximab in a patient with Crohn's disease. Rosi YL; Lowe L; Kang S J Dermatolog Treat; 2005 Feb; 16(1):58-61. PubMed ID: 15897171 [TBL] [Abstract][Full Text] [Related]
18. Autoinflammatory syndromes associated with hidradenitis suppurativa and/or acne. Vinkel C; Thomsen SF Int J Dermatol; 2017 Aug; 56(8):811-818. PubMed ID: 28345207 [TBL] [Abstract][Full Text] [Related]